CellCentric syndicate expands ahead of Phase III myeloma push: Venture Report

A growing roster of investors has backed CellCentric in its new $220 million series D round as the biotech aims to start a Phase III trial of a potential first-in-class therapy for late-line multiple myeloma.

Venrock Healthcare Capital Partners is leading the syndicate as Cambridge, U.K.-based CellCentric Ltd. tests inobrodib, its small molecule dual inhibitor of EP300 and CREBBP, in the Phase II DOMMINO-1 study, conducted in the U.K. and U.S. The company expects to start a global Phase III trial, DOMMINO-2, this year...